Mark R. Underwood

TL;DR: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group.

TL;DR: Findings demonstrate that S/GSK1349572 would be classified as a next-generation drug in the integrase inhibitor class, with a resistance profile markedly different from that of first-generation integrase inhibitors.

TL;DR: Dolutegravir-rilpivirine was non-inferior to CAR over 48 weeks in participants with HIV suppression and showed a safety profile consistent with its components, which supports the use of this two-drug regimen to maintain HIV suppression.

TL;DR: The dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations are determined, consistent with the potential for DTG to have a higher genetic barrier to resistance and evidence that the INI off-rate may be an important component of the mechanism of INI resistance.

TL;DR: In vitro selection experiments with DTG using viruses of subtypes B, C, and A/G and showed that the most common mutation to emerge was R263K, which does confer low-level resistance to DTG and decreased integration in cell culture without altering reverse transcription.